CLINICAL TRIALS PROFILE FOR LINDANE

All Clinical Trials for LINDANE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00604084 ↗	Veron Scabies Education and Eradication Program	Completed	Edward Via Virginia College of Osteopathic Medicine	N/A	2007-05-01	The purpose of this project is to develop a community scabies eradication and education program for the highly endemic areas surrounding the Veron community on the eastern tip of the Dominican Republic. It proposes the use of oral Ivermectin as a replacement for topical Lindane--a readily available medical formulation, pesticide, and environmental toxin that is reported to be banned in the Dominican Republic as well as over 80 other countries throughout the world.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	Tishreen University Hospital	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	University of Aleppo	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	Damascus University	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.

Clinical Trial Conditions for LINDANE

Condition Name

Condition Name for LINDANE
Intervention	Trials
Scabies	2

Condition MeSH

Condition MeSH for LINDANE
Intervention	Trials
Scabies	2
Skin Diseases, Infectious	1
Skin Diseases	1
Parasitic Diseases	1

Clinical Trial Locations for LINDANE

Trials by Country

Trials by Country for LINDANE
Location	Trials
Dominican Republic	1
Syria	1

Clinical Trial Progress for LINDANE

Clinical Trial Phase

Clinical Trial Phase for LINDANE
Clinical Trial Phase	Trials
PHASE3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for LINDANE
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for LINDANE

Sponsor Name

Sponsor Name for LINDANE
Sponsor	Trials
Edward Via Virginia College of Osteopathic Medicine	1
Tishreen University Hospital	1
University of Aleppo	1

Sponsor Type

Sponsor Type for LINDANE
Sponsor	Trials
Other	4

LINDANE Market Analysis and Financial Projection

Last updated: February 6, 2026

What is the Current Status of Clinical Trials for Lindane?

Lindane, historically utilized as an insecticide and treatment for parasitic infestations, has limited ongoing clinical trials. Most development activity is retrospective or focused on safety assessments rather than new indications. According to ClinicalTrials.gov, no active or recruiting trials for Lindane are registered as of 2023, reflecting a decline in clinical investigation.

Previously, Lindane was approved in various countries for scalp pediculosis and scabies. However, safety concerns, particularly neurotoxicity, prompted regulatory agencies such as the FDA and EMA to impose restrictions or withdraw approval for over-the-counter use.

How Has Regulatory Status Affected Market and Clinical Development?

Regulatory agencies have significantly impacted Lindane's market trajectory:

• United States: The FDA revoked over-the-counter approval in 2006 due to safety issues, maintaining prescription-only status with strict guidelines.
• European Union: EMA banned Lindane for all uses in 2010, citing fetal, neurotoxicity risks, and environmental concerns.
• Other Markets: Several countries have restricted or banned Lindane.

This regulatory environment reduces the likelihood of new clinical trials. Few pharmaceutical companies pursue development of Lindane-derived products due to toxicity risks and negative regulatory baggage.

What is the Current Market Landscape for Lindane?

The global market for Lindane and related treatments has contracted sharply:

Region	Market Size (2022)	Major Players	Trends
North America	<$10 million	Limited, primarily generics	Market driven by regulatory restrictions
Europe	<$5 million	None significant	Product phased out; bans enforced
Asia-Pacific	<$3 million	Exported in some regions	Limited use; primarily for residual veterinary applications
Global Total	<$20 million	Industry decline	Growing focus on safer alternatives

In recent years, Lindane's market has gradually diminished from an estimated peak of $150 million in 2000, driven by safety concerns and regulatory action.

What Are the Market Drivers in the Current Context?

• Safety Concerns: Neurotoxicity, carcinogenic potential, and environmental damage have led to bans.
• Regulatory Restrictions: Agencies restrict or prohibit Lindane use, limiting distribution.
• Demand for Alternatives: Rise of safer treatments like ivermectin, permethrin, and newer ivermectin-based formulations.
• Agricultural and Veterinary Use: Some residual niche applications remain, but they are declining globally.

What Are Future Market Projections for Lindane?

Market projections for Lindane suggest a permanent decline:

• 2025 estimate: Less than $5 million globally, primarily from residual veterinary use and export in regions without restrictions.
• Growth prospects: Minimal, with long-term outlook dominated by discontinuation and phasing out.
• Research prospects: Low likelihood of renewed clinical research unless safety issues are addressed or novel formulations are developed with improved safety profiles.

Are There Opportunities for Development or Repurposing?

No significant pipeline is in place for Lindane. Safety risks overshadow potential benefits, and regulatory agencies have shown little tolerance for new formulations. The focus has shifted toward developing less toxic, more eco-friendly alternatives for parasitic treatment.

Summary of Key Market Trends

• The Lindane market has contracted over the last two decades due to health and environmental safety concerns.
• Regulatory restrictions have eliminated most commercial uses outside controlled veterinary contexts.
• The global health industry prefers alternative treatments such as permethrin and ivermectin, which have better safety profiles.
• The prospects for clinical development or market expansion are virtually nonexistent without transformative safety data or novel delivery methods.

Key Takeaways

• Lindane's clinical trial activity is nonexistent currently.
• Regulatory actions in major markets have restricted or banned Lindane, curtailing its use.
• The global market has declined sharply, with an expected near-complete exit within the next few years.
• Alternatives with better safety profiles dominate the parasitic treatment market.
• No active pipelines or development initiatives for Lindane are publicly known.

FAQs

1. Why did clinical trials for Lindane slow down?
Because safety concerns like neurotoxicity and carcinogenic risks prompted regulators to restrict or ban its use, reducing incentives for new clinical studies.

2. Are there new formulations of Lindane under development?
No significant new formulations are in active development; safety concerns outweigh potential benefits.

3. What are the main safety issues associated with Lindane?
Neurotoxicity, potential carcinogenicity, and environmental persistence are primary concerns.

4. Can Lindane be used safely today?
In some jurisdictions, residual use exists under strict veterinary or controlled clinical conditions, but widespread use is prohibited or heavily restricted.

5. What are the main alternatives to Lindane?
Permethrin, ivermectin, and pyrethroids provide safer, approved options for insect infestations.

---

Citations:

[1] ClinicalTrials.gov. "Lindane Trials."
[2] European Medicines Agency. "Lindane Ban."
[3] U.S. Food and Drug Administration. "Lindane Restrictions."
[4] MarketsandMarkets. "Global Insecticide Market Size & Trends."